Charlotte's Web to establish scientific advisory board in September

Charlotte's Web Holdings Inc. (TSX: CWEB) (OTCQB: CWBHF) announced plans to establish a Scientific Advisory Board that will commence work in September 2025. The board will guide the company's research and development agenda and clinical initiatives for its hemp-derived CBD products.

The Louisville, Colorado-based company said the advisory board will support its medical channel strategy and help create Continuing Medical Education content for healthcare professionals. The initiative aims to address patient care gaps by offering practitioner-informed options for managing health issues including pain, anxiety, and sleep problems.

Dr. Marcel Bonn-Miller, the company's Chief Scientific Officer, will lead the board's development. Bonn-Miller has over 20 years of experience in cannabinoid research and has published approximately 200 research papers.

"The establishment of our Scientific Advisory Board is a critical step in advancing the clinical relevance of hemp-based therapeutics," Bonn-Miller said. "Our focus is on translating rigorous cannabinoid research into real-world solutions."

The board will also strengthen Charlotte's Web's partnership with DeFloria Inc., a collaboration that includes Ajna BioSciences PBC. The partnership focuses on developing AJA001, a full-spectrum CBD hemp extract as a treatment for irritability associated with autism spectrum disorder. The botanical pharmaceutical candidate has received FDA approval to proceed with Phase 2 clinical trials.

Charlotte's Web CEO Bill Morachnick said the advisory board represents a step forward in the company's commitment to expanding patient access to plant-based therapeutics. The company maintains partnerships with the Realm of Caring organization and operates a vertically integrated business model for quality control.

You May Also Be Interested In

• Greenland Energy adds Carol Craig to board of directors
• Diana Shipping urges Genco shareholders to vote against poison pill
• Enliven Therapeutics launches $250 million public stock offering